Use of angiotensin II receptor antagonists, especially telmisartan, in order to increase insulin sensitivity

Original document(22 pages) 中文版

The invention relates to the use of angiotensin II receptor antagonists for the treatment of people who have been diagnosed with type 2 diabetes mellitus, or are thought to have prediabetes, in order to prevent diabetes or for the treatment of metabolic syndrome and the resistance of insulin in patients having normal blood pressure.

Application Number 申请号	200480022096	Application Date 申请日	2004.07.24
Title 名称	Use of angiotensin II receptor antagonists, especially telmisartan, in order to increase insulin sensitivity
Publication Number 公开号	1829511	Publication Date 公开日	2006.09.06
Approval Pub. Date		Granted Pub. Date
International Classification 分类号	A61K31/416,A61P3/10,A61P5/50,A61P9/12
Applicant(s) Name 申请人	Boehringer Ingelheim Int
Address 地址
Inventor(s) Name 发明人	Kauschke Stefan, Mark Michael, Kintscher Ulrich, Schupp Michael
Attorney & Agent 代理人	fan menge wu xiaonan

Pharmaceutical compositions for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases
Medicinal composition containing triazole compound
5-membered heterocycle-based p-38 inhibitors
CCI-779 lyophilized formulations
Use of tripolidine in providing refreshedness on waking
S 2-'4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatement of obesity
Guanidino-substituted quinazolinone compounds as MC4-R agonists
Compounds, formulations, and methods for treating or preventing rosacea
Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use

Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.